- Home
- SNSE vs SYNX Comparison
SNSE vs SYNX Comparison
Compare SNSE & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- SYNX
- Stock Information
- Founded
- SNSE 2005
- SYNX 2005
- Country
- SNSE United States
- SYNX Israel
- Employees
- SNSE N/A
- SYNX N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- SYNX
- Sector
- SNSE Health Care
- SYNX
- Exchange
- SNSE Nasdaq
- SYNX Nasdaq
- Market Cap
- SNSE 10.8M
- SYNX 11.4M
- IPO Year
- SNSE 2021
- SYNX 2024
- Fundamental
- Price
- SNSE $8.17
- SYNX $1.64
- Analyst Decision
- SNSE Strong Buy
- SYNX
- Analyst Count
- SNSE 3
- SYNX 0
- Target Price
- SNSE $86.67
- SYNX N/A
- AVG Volume (30 Days)
- SNSE 12.9K
- SYNX 136.0K
- Earning Date
- SNSE 08-05-2025
- SYNX 05-14-2025
- Dividend Yield
- SNSE N/A
- SYNX N/A
- EPS Growth
- SNSE N/A
- SYNX N/A
- EPS
- SNSE N/A
- SYNX N/A
- Revenue
- SNSE N/A
- SYNX $9,094,000.00
- Revenue This Year
- SNSE N/A
- SYNX $32.35
- Revenue Next Year
- SNSE N/A
- SYNX N/A
- P/E Ratio
- SNSE N/A
- SYNX N/A
- Revenue Growth
- SNSE N/A
- SYNX 19.14
- 52 Week Low
- SNSE $5.00
- SYNX $1.56
- 52 Week High
- SNSE $17.40
- SYNX $6.49
- Technical
- Relative Strength Index (RSI)
- SNSE 50.67
- SYNX 42.63
- Support Level
- SNSE $8.76
- SYNX $1.60
- Resistance Level
- SNSE $9.27
- SYNX $1.76
- Average True Range (ATR)
- SNSE 0.52
- SYNX 0.12
- MACD
- SNSE -0.00
- SYNX -0.01
- Stochastic Oscillator
- SNSE 42.84
- SYNX 11.22
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.